When to Order Imaging for Noninvasive Clinical Staging of Primary Lung Cancer: ACR Appropriateness Decoded

When to Order Imaging for Noninvasive Clinical Staging of Primary Lung Cancer: ACR Appropriateness Decoded

It’s late in the shift, and a new patient presents with a lung mass found incidentally on a prior study. The diagnosis of primary lung cancer is suspected, and the next critical step is accurate clinical staging to guide therapy. The choice between PET/CT, dedicated CTs of the chest and abdomen, or brain MRI can feel complex, with implications for treatment planning, patient prognosis, and radiation exposure. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria to help you select the most effective noninvasive imaging pathway for your patient.

What Does ACR Noninvasive Clinical Staging of Primary Lung Cancer Cover?

This ACR guideline focuses specifically on the initial, noninvasive clinical staging of a newly diagnosed or highly suspected primary lung cancer before any treatment has been initiated. It provides evidence-based recommendations for determining the extent of disease, including the primary tumor (T), nodal involvement (N), and distant metastases (M). The criteria are broken down by the two major histological subtypes: non–small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC), as their patterns of spread and management strategies differ significantly.

These recommendations do not apply to lung cancer screening, evaluation of a solitary pulmonary nodule, post-treatment surveillance, or restaging after neoadjuvant therapy. The focus is strictly on the comprehensive, upfront imaging workup required to establish the baseline TNM stage, which is fundamental for multidisciplinary tumor board discussions and determining whether a patient is a candidate for curative-intent surgery, definitive chemoradiation, or systemic therapy.

What Imaging Should I Order for Noninvasive Clinical Staging of Primary Lung Cancer? Recommendations by Clinical Scenario

Accurate staging is paramount in lung cancer, and the ACR provides clear guidance based on histology. The primary goal is to identify the full extent of disease to inform the optimal treatment strategy.

For a patient with noninvasive initial clinical staging of non–small-cell lung carcinoma (NSCLC), the ACR identifies several studies as Usually Appropriate. An FDG-PET/CT from the skull base to mid-thigh is a cornerstone of staging, as it provides whole-body metabolic information to detect nodal and distant metastatic disease in a single examination. For detailed anatomic evaluation of the primary tumor and mediastinum, a CT chest with IV contrast is also rated as Usually Appropriate. To assess for the common site of brain metastases, an MRI head without and with IV contrast is the preferred modality. A non-contrast chest CT is also considered usually appropriate, often serving as the initial diagnostic study that identifies the primary mass.

Several other studies are rated as May Be Appropriate for NSCLC staging. These are typically used when a primary modality is contraindicated or when findings are equivocal. For example, a CT of the abdomen and pelvis with IV contrast may be used if PET/CT is unavailable or to further characterize an adrenal lesion. A whole-body bone scan can be considered to evaluate for osseous metastases, though it has largely been supplanted by the superior sensitivity of PET/CT. MRI of the abdomen or chest may be appropriate for problem-solving, such as evaluating liver lesions or assessing chest wall invasion.

For a patient with noninvasive initial clinical staging of small-cell lung carcinoma (SCLC), the imaging recommendations are similar, reflecting the need for a comprehensive systemic evaluation due to SCLC’s aggressive nature and high propensity for early metastasis. The ACR rates FDG-PET/CT skull base to mid-thigh as Usually Appropriate for detecting extensive-stage disease. A CT chest with IV contrast is essential for evaluating the primary tumor and mediastinal involvement. Given the high incidence of brain metastases in SCLC, an MRI head without and with IV contrast is also Usually Appropriate. Finally, a CT abdomen and pelvis with IV contrast is considered a standard component of the workup to assess for common metastatic sites like the liver and adrenal glands.

Modalities rated as May Be Appropriate for SCLC staging serve similar problem-solving roles as in NSCLC. A whole-body bone scan may be used if PET/CT is not available. A non-contrast chest CT may be sufficient in certain contexts, and various MRI and CT protocols can be used to clarify specific findings. For both NSCLC and SCLC, a simple chest radiograph is rated Usually Not Appropriate for staging, as it lacks the sensitivity and detail required for TNM assessment.

ACR Imaging Recommendations Table

Adult vs. Pediatric Noninvasive Clinical Staging of Primary Lung Cancer Imaging: Radiation Dose Tradeoffs

Primary lung cancer is exceedingly rare in the pediatric population, but when it occurs, imaging decisions must carefully balance diagnostic necessity with the principles of radiation safety. The ACR provides pediatric-specific Relative Radiation Level (RRL) estimates, which often fall into higher tiers or have different mSv ranges compared to adults for the same CT-based study. This reflects the increased radiosensitivity of developing tissues and the longer life expectancy over which potential stochastic effects of radiation could manifest.

For example, a CT chest is rated as ☢ ☢ ☢ (1-10 mSv) for adults but ☢ ☢ ☢ ☢ (3-10 mSv [ped]) for children. This difference underscores the importance of the As Low As Reasonably Achievable (ALARA) principle. Protocols must be specifically tailored for pediatric patients to minimize dose through adjustments in kVp, mAs, and scan length. When clinically appropriate and available, non-ionizing modalities like MRI should be considered. For any necessary CT or nuclear medicine study, the potential benefit of accurate staging must clearly outweigh the long-term radiation risks, a calculation that is especially critical in younger patients.

Imaging Protocol Details for Noninvasive Clinical Staging of Primary Lung Cancer

Once you’ve decided on the right study, the specific imaging protocol is critical for obtaining diagnostic-quality images. Details like contrast timing, slice thickness, and reconstruction algorithms can significantly impact the ability to accurately stage the disease. Our protocol guides cover technique, contrast, and reading principles for the studies recommended above:

• CT Brain Without Contrast

Tools to Help You Order the Right Study

Navigating imaging guidelines and radiation dose considerations can be streamlined with the right digital tools. GigHz offers several resources designed to support clinical decision-making at the point of care.

For clinical questions that fall outside the scope of lung cancer staging, the ACR Appropriateness Criteria Lookup provides a searchable interface to access the full library of ACR guidelines. This can help you find evidence-based recommendations for hundreds of clinical scenarios.

To ensure studies are performed correctly, the Imaging Protocol Library offers detailed, step-by-step protocols for a wide range of CT, MRI, and other imaging procedures. This resource is valuable for standardizing techniques and ensuring high-quality image acquisition.

When discussing imaging options with patients, especially concerning radiation, the Radiation Dose Calculator is a useful aid. It helps estimate cumulative radiation exposure from various imaging studies, facilitating more informed conversations about the risks and benefits of a recommended diagnostic workup.

Why is FDG-PET/CT so important for lung cancer staging?

FDG-PET/CT is a powerful hybrid imaging modality that combines functional (PET) and anatomic (CT) information. It is highly sensitive for detecting metabolically active cancer cells throughout the body. For lung cancer, it is superior to conventional imaging (CT and bone scan) for identifying unsuspected mediastinal lymph node involvement and distant metastases, which can fundamentally change the patient’s stage and treatment plan, often preventing futile surgery in patients with advanced disease.

When is brain MRI preferred over CT for detecting brain metastases?

MRI without and with IV contrast is significantly more sensitive than contrast-enhanced CT for detecting brain metastases, especially small lesions. The ACR rates MRI as “Usually Appropriate” for both NSCLC and SCLC staging for this reason. A contrast-enhanced CT of the head is only considered “May Be Appropriate,” typically reserved for patients who have contraindications to MRI (e.g., incompatible hardware) or in situations where MRI is not readily available.

Is a chest radiograph ever sufficient for staging lung cancer?

No. The ACR rates a chest radiograph as “Usually Not Appropriate” for the clinical staging of either NSCLC or SCLC. While a chest X-ray may be the initial study that discovers a lung mass, it lacks the spatial resolution and detail to accurately assess the size of the primary tumor, its invasion into adjacent structures, mediastinal and hilar lymph nodes, or small pleural effusions. Cross-sectional imaging with CT is required for proper T and N staging.

What are the key differences in the imaging workup for NSCLC versus SCLC?

The workups are very similar, emphasizing a comprehensive search for metastatic disease. Both rely heavily on PET/CT, contrast-enhanced chest CT, and brain MRI. One subtle difference in the ACR criteria is that for SCLC, a contrast-enhanced CT of the abdomen and pelvis is also listed as “Usually Appropriate,” reflecting the aggressive nature and common metastatic spread of SCLC to the liver and adrenal glands. While this is often performed for NSCLC as well (frequently as part of the PET/CT), its explicit high rating for SCLC underscores the need for meticulous evaluation of the abdomen in these patients.

Why is intravenous contrast typically necessary for chest and abdominal CTs in lung cancer staging?

Intravenous contrast enhances the visibility of blood vessels and vascular organs, which is critical for several aspects of staging. In the chest, it helps distinguish lymph nodes from vessels, delineate the extent of tumor invasion into vascular structures like the pulmonary artery or aorta, and identify enhancing tumor tissue. In the abdomen, contrast is essential for detecting and characterizing metastases in solid organs, particularly the liver and adrenal glands, which are common sites of spread.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026